Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by symptoms such as abdominal pain, diarrhea, constipation, and indigestion. Given its unclear etiology and pathogenesis, and the absence of specific biomarkers, clinical diagnosis and treatment of IBS continue to pose significant challenges. In recent years, metabolomics technology, known for its non-invasive, high-throughput, high-precision, and highly reproducible features, has been widely applied in the diagnosis, treatment, and prognosis of various diseases. Therefore, metabolomics technology is expected to offer novel insights and methodologies for the biological mechanism research, diagnosis, and treatment of IBS. This article reviews recent advancements in the application of metabolomics to IBS, exploring its potential value in the clinical diagnosis and treatment of children with this condition.
肠易激综合征（irritable bowel syndrome, IBS）是一种常见的功能性胃肠病，主要表现为腹痛、腹泻、便秘以及消化不良等症状。由于其病因和发病机制尚不清楚，并且缺乏特异性的生物标志物，使其临床诊断和治疗仍然存在较大困难。近年来，代谢组学技术因其无创、高通量、高精度、高可重复性等特点，在疾病诊断、治疗及预后评估方面得到了广泛应用。代谢组学技术有望为IBS的生物学机制研究、诊断及治疗提供新思路和方法。该文综述近年代谢组学在IBS中的应用及研究进展，并探讨其在儿童IBS临床诊断和治疗中的潜在应用价值。.
Keywords: Biomarker; Child; Irritable bowel syndrome; Metabolic pathway; Metabolomics.